NexImmune has dosed the first patient participating in its Phase 1/2 trial of NEXI-002, the company’s investigational T-cell therapy for multiple myeloma. The trial (NCT04505813), which is recruiting participants at several sites across the U.S., aims to enroll 22 to 28 patients with relapsed or refractory multiple myeloma, who failed to respond to at least three lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. More information about trial contacts and…
You must be logged in to read/download the full post.
The post 1st Patient Dosed With Investigational T-cell Therapy NEXI-002 in Phase 1/2 Trial appeared first on BioNewsFeeds.